πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

672 results for β€œNan” Clear

  1. Encapsulated Calcium

    United Therapeutics Europe Ltd

    Pregnancy

    phase 1 other completed

    1 trial

  2. Engineered mitochondrial vaccine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Solid Tumor Malignancies

    phase 1 mab active

    1 trial

  3. Etrumadenant

    Arcus Biosciences

    Healthy Participants

    phase 1 small molecule completed

    2 trials

  4. Etrumadenant

    Arcus Biosciences

    TNBC - Triple-Negative Breast Cancer

    phase 1 small molecule completed

    1 trial

  5. Etrumadenant

    Arcus Biosciences

    Non Small Cell Lung Cancer Metastatic

    phase 1 small molecule completed

    1 trial

  6. Etrumadenant

    Arcus Biosciences

    Non-small Cell Lung Cancer

    phase 1 small molecule completed

    1 trial

  7. Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059οΌ‰οΌ‰

    The First People's Hospital of Lianyungang

    T2DM

    phase 1 small molecule active

    1 trial

  8. FHD-286

    Foghorn Therapeutics

    Advanced Hematologic Malignancy

    phase 1 small molecule active

    1 trial

  9. Fluconazole

    ENANTA PHARMACEUTICALS INC

    NASH - Nonalcoholic Steatohepatitis

    phase 1 small molecule completed

    1 trial

  10. Fludarabine

    Zafatek

    Hematologic Malignancies

    phase 1 small molecule completed

    1 trial

  11. G207

    BRIGHT MINDS BIOSCIENCES INC.

    Supratentorial Neoplasms, Malignant

    phase 1 mab completed

    1 trial

  12. GEN1042

    Genmab A/S

    Malignant Solid Tumor

    phase 1 mab active

    1 trial

  13. HEC89736

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Relapsed or Refractory B-cell Hematologic Malignancies

    phase 1 small molecule terminated

    1 trial

  14. HTLP-onco-adult - A phase I/II Study evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adult patients with hematologic malignancies

    Pari Pharma GmbH

    hematologic malignancies ; acute myeloid leukemias

    phase 1 other active

    1 trial

  15. Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Malignant Tumor

    phase 1 small molecule active

    1 trial

  16. ICG-Cisplatin Nanoprobe (NIR-II NanoM)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Cancer, Adult

    phase 1 small molecule active

    1 trial

  17. IL-22BP mRNA vaccine injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Refractory Malignant Solid Tumors

    phase 1 mab active

    1 trial

  18. INO-3106, INO-9012

    INOVIO PHARMACEUTICALS, INC.

    Aerodigestive Precancerous Lesions and Malignancies

    phase 1 mab completed

    1 trial

  19. INTERACT MESO: Intraperitoneal Paclitaxel for Patients with Primary Malignant Peritoneal Mesothelioma – a Phase I/II Dose Escalation and Safety Study

    Disc Medicine

    Patients with malignant peritoneal mesothelioma

    phase 1 other active

    1 trial

  20. IXAZOMIB

    Takeda

    Advanced Non-hematologic Malignancies

    phase 1 small molecule completed

    1 trial

  21. Ixazomib 2.5 mg

    Takeda

    Nonhematologic Malignancies

    phase 1 small molecule completed

    1 trial

  22. JY306 universal NK cell injection

    The First People's Hospital of Lianyungang

    Relapsed or Refractory Hematological Malignancies

    phase 1 mab active

    1 trial

  23. KO-947

    Kura Oncology

    Advanced Malignant Neoplasm

    phase 1 small molecule terminated

    1 trial

  24. KPT-330

    Karyopharm Therapeutics Inc

    Hematological Malignancies

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources